VIR News and Press, Vir Biotechnology Inc. From 12/21/22

SAN FRANCISCO, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it has achieved the target enrollment of approximately 3,000 participants in the groundbreaking Phase 2 PENINSULA ( P rev E ntio N of I ll N es S ...

Vir Biotechnology (NASDAQ: VIR) and Axonics (NASDAQ: AXNX) are two of the fastest-growing healthcare companies in terms of revenue. Vir raised $142.9 million when it went public with an initial public offering (IPO) in 2019, while Axonics raised $120 million with its IPO in 2018...

Summary The pharmaceutical and biotechnology subsector is undervalued by about 17% relative to 11-year averages. Healthcare equipment and life science tools are overvalued by about 25% regarding the same metrics. Fast facts on IDNA. 10 stocks cheaper than their peers in No...

SAN FRANCISCO, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it ranked first on the 2022 Deloitte Technology Fast 500 ™ , a list of the fastest-growing technology, media, telecommunications, life sciences, fintech and energy tech comp...

The main difference in the Bill & Melinda Gates Foundation portfolio in Q3 2022 is the addition of ~14.3M shares of LumiraDx ( NASDAQ: LMDX ), a point-of-care diagnostics company, according to the foundation's 13F filing for Q3 2022. In addition, the philanthropic ...

The following slide deck was published by Vir Biotechnology, Inc. in conjunction with this event. For further details see: Vir Biotechnology (VIR) Presents at AASLD The Liver Meeting 2022

– Data from multiple ongoing trials evaluating Vir’s two novel HBV therapies continue to demonstrate substantial reductions in hepatitis B surface antigen (HBsAg) with no new safety signals – – Preliminary data to-date show that 30.8% of participants receiv...

Shares of biopharma company Vir Biotechnology (NASDAQ: VIR) are up 18.9% as of 3:42 p.m. ET Friday following Thursday's post-close release of its third-quarter results. Earnings dramatically exceeded expectations due to strong sales of a COVID-19 treatment, but it's Vir's pipeline a...

Vir Biotechnology ( NASDAQ: VIR ) on Thursday reported a big Q3 beat on both top and bottom line, as a surge in revenue from the company's collaboration with GSK helped overall revenue more than double Y/Y. VIR stock rose 6.7% to $23.27 after hours. The compan...

Vir Biotechnology press release ( NASDAQ: VIR ): Q3 GAAP EPS of $1.30 beats by $1.37 . Revenue of $374.6M (+261.6% Y/Y) beats by $260.32M . As of September 30, 2022, excluding restricted cash, the Company had approximately $2.7B in cash, cash equivalents, inves...